GlassScriptPhysician profile
Nhuai C Le
NPI 1558358697
$3,280.72
in general payments reported to CMS, 2019-2025
24 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $415 · 2021: $603 · 2022: $776 · 2023: $457 · 2024: $229 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $822.60 | 2019-2025 | |
| Novo Nordisk INC | $563.57 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $466.12 | 2019-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.62 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $234.48 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $127.18 | 2022-2024 | Unithroid |
| Lilly USA, LLC | $118.84 | 2019-2024 | Jardiance, Zepbound |
| Amgen INC. | $86.59 | 2022-2023 | Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $85.90 | 2021-2022 | |
| Eisai INC. | $67.14 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $47.90 | 2023-2024 | Gemtesa |
| Glaxosmithkline, LLC. | $47.08 | 2021-2023 | Arexvy |
| Merck Sharp & Dohme LLC | $41.64 | 2019-2021 | |
| Astellas Pharma US INC | $37.64 | 2019-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $29.19 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $28.20 | 2022-2025 | Zoryve |
| Shire North American Group INC | $20.49 | 2019 | |
| Intra-Sana Laboratories | $19.29 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Seqirus USA INC | $17.48 | 2025 | Fluad, Flucelvax |
| Bayer Healthcare Pharmaceuticals INC. | $17.06 | 2021 | |
| Abbott Laboratories | $15.00 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.84 | 2019 | |
| Currax Pharmaceuticals LLC | $14.14 | 2023 | Contrave |
| Adlon Therapeutics L.P. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nhuai Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.